COMP <GO>
INCY vs JNJ // FORWARD P/E MULTIPLE
Incyte Corp. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: INCY 9
— JNJ 5
▲ FORWARD P/E MULTIPLE LEADER: INCY
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
forward-pe
15.5x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCY VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCY | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.80% | 67.90% | +24.90 | INCY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.40% | 25.50% | +16.90 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 18.5x | -6.00 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 4.99% | 2.97% | +2.02 | INCY | /fcf-yield <GO> |
| Operating Margin | 29.50% | 34.70% | -5.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 25.00% | 28.50% | -3.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 21.20% | 6.00% | +15.20 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.04 | 5.59 | +4.45 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | INCY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.5 | 60.4 | -2.84 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.08 | -0.07 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 15.5x | 23.0x | -7.50 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.68B | $662.49B | -$638.82B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCY REV | JNJ REV | INCY GROSS % | JNJ GROSS % | INCY FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.14B | $94.19B | 92.8% | 67.9% | $1.18B | $19.70B |
| FY 2024 | $4.24B | $88.82B | 92.6% | 69.1% | $144.5M | $19.84B |
| FY 2023 | $3.70B | $85.16B | 44.0% | 44.0% | $330.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCY // BETA 1.01
JNJ // BETA 1.08